Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company dedicated to developing novel cancer therapies. Leveraging their proprietary PLK1 inhibition technology, Cardiff Oncology focuses on creating innovative treatments for various cancers with significant unmet medical needs.
Cardiff Oncology's lead therapeutic asset is onvansertib, a highly selective Polo-like kinase 1 (PLK1) inhibitor. This investigational drug is currently being evaluated in clinical trials for its effectiveness in treating multiple types of cancer, including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
Recent achievements include promising clinical data for onvansertib monotherapy and combination therapy in mPDAC and SCLC trials. The mPDAC Phase 2 trial reported a 19% objective response rate (ORR) and a median progression-free survival (mPFS) of 5.0 months, compared to historical controls with an ORR of 7.7% and mPFS of 3.1 months. In SCLC, onvansertib monotherapy has demonstrated encouraging single-agent activity.
Cardiff Oncology continues to expand its clinical programs and research partnerships. They announced a first-line trial in mPDAC in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute, exploring both monotherapy and combination therapy with standard care. Furthermore, the company highlights an ongoing Phase 1b/2 study for KRAS-mutated mCRC, which has shown a favorable safety profile and promising efficacy results.
Financially, Cardiff Oncology reported a strong cash position with approximately $81.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023. Their operational strategy is supported by partnerships and ongoing research endeavors, which are projected to fund operations into 2025.
The company's forward-looking initiatives include the advancement of their lead program in RAS-mutated mCRC to the first-line setting and continuous exploration of onvansertib's potential in various cancer treatments. Investors and stakeholders can stay updated through regular business updates and conference calls hosted by Cardiff Oncology.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
What is Cardiff Oncology's primary focus?
What is onvansertib?
Which cancers is Cardiff Oncology targeting with onvansertib?
What are the recent clinical achievements of Cardiff Oncology?
What is the financial condition of Cardiff Oncology?
What are the upcoming milestones for Cardiff Oncology?
How can investors stay updated about Cardiff Oncology?
What partnerships does Cardiff Oncology have?
What is the significance of PLK1 in cancer treatment?
Where can more information about Cardiff Oncology be found?
